Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (Xcimzane ™) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion




Approved and pending patent applications


Biosimilars under development

Capital Markets Day 17 May, 2021

At Xbrane Biopharma

Press Releases

13 Aug 2021

Xbrane Biopharma releases interim report for January – June 2021

11 Aug 2021

Invitation to presentation of Xbrane Biopharma’s interim report January – June, 2021 on August 13, 2021.

31 Jul 2021

Change of number of shares and votes in Xbrane

02 Jul 2021

Xbrane Biopharma certified as a Great Place to Work®

30 Jun 2021

Xbrane Biopharma has carried out a directed share issue raising gross proceeds of SEK 380 millions

30 Jun 2021

Xbrane Biopharma announces intention to carry out a directed share issue

30 Jun 2021


27 Jun 2021

Xlucane™ meets the primary endpoint in the pivotal Phase III trial with Xlucane™ – regulatory submission in EU and US planned for second half of 2021

16 May 2021

Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum.